{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:33:16Z","timestamp":1788445996068,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA267467"],"award-info":[{"award-number":["CA267467"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA279713"],"award-info":[{"award-number":["R01CA279713"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA267467"],"award-info":[{"award-number":["CA267467"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA275691"],"award-info":[{"award-number":["R37CA275691"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001784","name":"Pancreatic Cancer Action Network","doi-asserted-by":"publisher","award":["167025ABEL"],"award-info":[{"award-number":["167025ABEL"]}],"id":[{"id":"10.13039\/100001784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002135","name":"Hirshberg Foundation for Pancreatic Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002135","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SAS Foundation for Cancer Research"},{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We previously identified an oncogenic role for the transcription factor HNF1A in pancreatic ductal adenocarcinoma (PDAC). However, the role of HNF1A in the metastatic progression of PDAC remains unknown and targeting modalities for HNF1A-dependent phenotypes have yet to be identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transwell chambers were used to assess the effects of HNF1A and FGFR4 modulation on the migration and invasion of ATCC and patient-derived PDAC cells in vitro. An intrasplenic injection xenograft model was used to evaluate the impact of HNF1A knockdown and overexpression on metastatic tumor burden. Single-cell RNA sequencing (scRNA-seq), tissue microarray (TMA) data, and UMAP spatial profiling were used to identify FGFR4 as an HNF1A target gene upregulated in metastatic cells. RNAi and two FGFR4 inhibiting modalities (H3B-6527 and U3-1784) were utilized to demonstrate the efficacy of FGFR4 inhibiting agents at reducing HNF1A-driven metastasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Knockdown of HNF1A significantly decreases and HNF1A overexpression significantly increases PDAC cell migration and invasion. In vivo studies show that HNF1A knockdown significantly abrogates metastasis, while overexpression significantly promotes metastasis. scRNA-seq shows that FGFR4 is upregulated in metastatic PDAC cells and staining for HNF1A and FGFR4 in a PDAC TMA reveals significant correlation between HNF1A and FGFR4 in PDAC patients. Further, knockdown and inhibition of FGFR4 significantly decreases HNF1A-mediated cell migration and invasion, and blocks HNF1A-driven metastasis in vivo\n                      <jats:italic>.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that HNF1A drives PDAC metastasis via upregulation of FGFR4, and FGFR4 inhibition is a potential mechanism to target metastasis in PDAC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-025-02408-5","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T05:03:04Z","timestamp":1753765384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Katherine J.","family":"Crawford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kennedy S.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Feigin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka K.","family":"Witkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan V.","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"2408_CR1","unstructured":"Cancer Stat Facts: Pancreatic Cancer. (n.d.). Retrieved from National Cancer Institute Surveillance, Epidemiology, and End Results Program: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html"},{"key":"2408_CR2","first-page":"1","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, et al. Pancreatic cancer Nat Rev Dis Prim. 2016;2:1\u201323.","journal-title":"Pancreatic cancer Nat Rev Dis Prim"},{"issue":"5662","key":"2408_CR3","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1126\/science.1089769","volume":"303","author":"DT Odom","year":"2004","unstructured":"Odom DT, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303(5662):1378\u201381.","journal-title":"Science."},{"key":"2408_CR4","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1128\/MCB.01389-08","volume":"29","author":"J-M Servitja","year":"2009","unstructured":"Servitja J-M, et al. Hnf1 (MODY3) Controls Tissue-Specific Transcriptional Programs and Exerts Opposed Effects on Cell Growth in Pancreatic Islets and Liver \u2020. Mol Cell Biol. 2009;29:2945\u201359.","journal-title":"Mol Cell Biol"},{"key":"2408_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2478\/enr-2019-0013","volume":"53","author":"T Valkovicova","year":"2019","unstructured":"Valkovicova T, Skopkova M, Stanik J, Gasperikova D. Novel insights into genetics and clinics of the HNF1A-MODY. Endocr Regul. 2019;53:110\u201334.","journal-title":"Endocr Regul"},{"key":"2408_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.33947","volume":"7","author":"EV Abel","year":"2018","unstructured":"Abel EV, et al. HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. Elife. 2018;7:1\u201335.","journal-title":"Elife"},{"key":"2408_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccell.2017.10.008","volume":"32","author":"S Shukla","year":"2017","unstructured":"Shukla S, et al. Aberrant activation of a gastrointestinal transcriptional circuit in prostate cancer mediates castration resistance. Cancer Cell. 2017;32:792\u2013806.","journal-title":"Cancer Cell"},{"key":"2408_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/hmg\/ddi057","volume":"14","author":"S Rebouissou","year":"2005","unstructured":"Rebouissou S, et al. Germline hepatocyte nuclear factor 1\u03b1 and 1\u03b2 mutations in renal cell carcinomas. Hum Mol Genet. 2005;14:603\u201314.","journal-title":"Hum Mol Genet"},{"key":"2408_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41422-019-0259-z","volume":"30","author":"S Teng","year":"2020","unstructured":"Teng S, et al. Tissue-specific transcription reprogramming promotes liver metastasis of colorectal cancer. Cell Res. 2020;30:34\u201349.","journal-title":"Cell Res"},{"key":"2408_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.14219","author":"C Cai","year":"2021","unstructured":"Cai C, et al. Hepatocyte nuclear factor HNF1A is a potential regulator in shaping the super-enhancer landscape in colorectal cancer liver metastasis. FEBS Lett. 2021. https:\/\/doi.org\/10.1002\/1873-3468.14219.","journal-title":"FEBS Lett"},{"issue":"54","key":"2408_CR11","doi-asserted-by":"publisher","first-page":"8251","DOI":"10.1038\/sj.onc.1206020","volume":"21","author":"RN Shah","year":"2002","unstructured":"Shah RN, Ibbitt JC, Alitalo K, Hurst HC. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1\u03b1. Oncogene. 2002;21(54):8251\u201361.","journal-title":"Oncogene."},{"key":"2408_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107590","volume":"214","author":"KM Levine","year":"2020","unstructured":"Levine KM, Ding K, Chen L, Oesterreich S. FGFR4: A promising therapeutic target for breast cancer and other solid tumors. Pharmacol Ther. 2020;214: 107590.","journal-title":"Pharmacol Ther"},{"key":"2408_CR13","doi-asserted-by":"crossref","unstructured":"Kostrzewa, M. & Muller, U. Genomic structure and complete sequence of the human FGFR4 gene. Mamm Genome. 1998;9(2):131\u20135.","DOI":"10.1007\/s003359900703"},{"key":"2408_CR14","doi-asserted-by":"publisher","first-page":"36713","DOI":"10.1371\/journal.pone.0036713","volume":"7","author":"DM French","year":"2012","unstructured":"French DM, Lin BC, Wang M, Adams C, Shek T. Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models. PLoS ONE. 2012;7:36713.","journal-title":"PLoS ONE"},{"key":"2408_CR15","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.1158\/0008-5472.CAN-12-4718","volume":"73","author":"R Liu","year":"2013","unstructured":"Liu R, et al. FGFR4 Promotes Stroma-Induced Epithelial-to-Mesenchymal Transition in Colorectal Cancer. Cancer Res. 2013;73:5926\u201335.","journal-title":"Cancer Res"},{"key":"2408_CR16","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.7150\/jca.12825","volume":"6","author":"S Shi","year":"2015","unstructured":"Shi S, et al. High Expression of FGFR4 Enhances Tumor Growth and Metastasis in Nasopharyngeal Carcinoma. J Cancer. 2015;6:1245\u201354.","journal-title":"J Cancer"},{"key":"2408_CR17","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1172\/JCI130323","volume":"130","author":"S Garcia-Recio","year":"2020","unstructured":"Garcia-Recio S, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J Clin Invest. 2020;130:4871\u201387.","journal-title":"J Clin Invest"},{"key":"2408_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.7150\/thno.82269","volume":"13","author":"X Chen","year":"2023","unstructured":"Chen X, et al. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC. Theranostics. 2023;13:1401\u201318.","journal-title":"Theranostics"},{"key":"2408_CR19","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.7150\/thno.57659","volume":"11","author":"Q He","year":"2021","unstructured":"He Q, et al. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation. Theranostics. 2021;11:5759\u201377.","journal-title":"Theranostics"},{"key":"2408_CR20","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","volume":"77","author":"JJ Joshi","year":"2017","unstructured":"Joshi JJ, et al. H3B\u20136527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. Cancer Res. 2017;77:6999\u20137013.","journal-title":"Cancer Res"},{"key":"2408_CR21","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1158\/1535-7163.MCT-18-0048","volume":"18","author":"R Bartz","year":"2019","unstructured":"Bartz R, et al. Preclinical Development of U3\u20131784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. Mol Cancer Ther. 2019;18:1832\u201343.","journal-title":"Mol Cancer Ther"},{"key":"2408_CR22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/diacare.46.10.1643","volume":"46","author":"S Yamada","year":"1997","unstructured":"Yamada S, et al. Identification of mutations in the hepatocyte nuclear factor (HNF)-1 alpha gene in Japanese subjects with IDDM. Diabetes. 1997;46:1643\u20137.","journal-title":"Diabetes"},{"key":"2408_CR23","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.celrep.2014.11.025","volume":"9","author":"GH Baek","year":"2014","unstructured":"Baek GH, et al. MCT4 Defines a Glycolytic Subtype of Pancreatic Cancer with Poor Prognosis and Unique Metabolic Dependencies. Cell Rep. 2014;9:2233\u201349.","journal-title":"Cell Rep"},{"key":"2408_CR24","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1158\/1078-0432.CCR-15-1883","volume":"22","author":"J Hutcheson","year":"2016","unstructured":"Hutcheson J, et al. Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease. Clin Cancer Res. 2016;22:3606\u201317.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2408_CR25","doi-asserted-by":"publisher","first-page":"102021.","DOI":"10.1016\/j.xpro.2022.102021","volume":"4","author":"M O\u2019Brien","year":"2023","unstructured":"O\u2019Brien M, Ernst M, Poh AR. An intrasplenic injection model of pancreatic cancer metastasis to the liver in mice. STAR protocols. 2023;4(1):102021.","journal-title":"STAR protocols."},{"key":"2408_CR26","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/gutjnl-2020-323014","volume":"71","author":"Z Xie","year":"2022","unstructured":"Xie Z, et al. Exosome-delivered CD44v6\/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment. Gut. 2022;71:568\u201379.","journal-title":"Gut"},{"key":"2408_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10585-017-9840-3","volume":"34","author":"K Sasaki","year":"2017","unstructured":"Sasaki K, et al. Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer. Clin Exp Metastasis. 2017;34:229\u201339.","journal-title":"Clin Exp Metastasis"},{"key":"2408_CR28","first-page":"109","volume":"1","author":"R Nicolle","year":"2024","unstructured":"Nicolle R, et al. Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study. EBioMedicine. 2024;1:109.","journal-title":"EBioMedicine."},{"key":"2408_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11523-023-00948-8","volume":"18","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, et al. First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors. Target Oncol. 2023;18:181\u201393.","journal-title":"Target Oncol"},{"key":"2408_CR30","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1159\/000487737","volume":"45","author":"J Huang","year":"2018","unstructured":"Huang J, et al. TGF-\u03b21 Promotes Hepatocellular Carcinoma Invasion and Metastasis via ERK Pathway-Mediated FGFR4 Expression. Cell Physiol Biochem. 2018;45:1690\u20139.","journal-title":"Cell Physiol Biochem"},{"key":"2408_CR31","doi-asserted-by":"publisher","first-page":"633453.","DOI":"10.3389\/fphar.2021.633453","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Novel regulatory factors and small-molecule inhibitors of FGFR4 in cancer. Front Pharmacol. 2021;12:633453.","journal-title":"Front Pharmacol."},{"key":"2408_CR32","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1535-7163.MCT-18-1291","volume":"18","author":"A Weiss","year":"2019","unstructured":"Weiss A, et al. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. Mol Cancer Ther. 2019;18:2194\u2013206.","journal-title":"Mol Cancer Ther"},{"key":"2408_CR33","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","volume":"9","author":"RD Kim","year":"2019","unstructured":"Kim RD, et al. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discov. 2019;9:1696\u2013707.","journal-title":"Cancer Discov"},{"key":"2408_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ccell.2018.12.010","volume":"35","author":"AA Connor","year":"2019","unstructured":"Connor AA, et al. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases. Cancer Cell. 2019;35:267-282.e7.","journal-title":"Cancer Cell"},{"key":"2408_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung KL, et al. Genomics-driven precision medicine for advanced pancreatic cancer: Early results from the COMPASS trial. Clin Cancer Res. 2018;24:1344\u201354.","journal-title":"Clin Cancer Res"},{"key":"2408_CR36","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/jamaoncol.2016.3916","volume":"3","author":"AA Connor","year":"2017","unstructured":"Connor AA, et al. Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma. JAMA Oncol. 2017;3:774\u201383.","journal-title":"JAMA Oncol"},{"key":"2408_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta F, et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature. 2016;538:378\u201382.","journal-title":"Nature"},{"key":"2408_CR38","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao L, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184:5031-5052.e26.","journal-title":"Cell"},{"issue":"1","key":"2408_CR39","doi-asserted-by":"publisher","first-page":"8444","DOI":"10.1038\/s41467-023-44126-w","volume":"14","author":"M Maurin","year":"2023","unstructured":"Maurin M. RBFOX2 deregulation promotes pancreatic cancer progression and metastasis through alternative splicing. Nat Commun. 2023;14(1):8444.","journal-title":"Nat. Commun."},{"key":"2408_CR40","unstructured":"DepMap 24Q4 Public. https:\/\/plus.figshare.com\/articles\/dataset\/DepMap_24Q4_Public\/27993248\/1."},{"key":"2408_CR41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41586-020-2023-4","volume":"583","author":"EC Partridge","year":"2020","unstructured":"Partridge EC, et al. Occupancy maps of 208 chromatin-associated proteins in one human cell type. Nature. 2020;583:720\u20138.","journal-title":"Nature"},{"issue":"3","key":"2408_CR42","doi-asserted-by":"publisher","first-page":"e12377","DOI":"10.1002\/2056-4538.12377","volume":"10","author":"J Rao","year":"2024","unstructured":"Rao J, et al. KRT81 and HNF1A expression in pancreatic ductal adenocarcinoma: investigation of predictive and prognostic value of immunohistochemistry-based subtyping. J Pathol Clin Res. 2024;10(3):e12377.","journal-title":"J Pathol Clin Res."},{"key":"2408_CR43","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1038\/s41388-022-02432-5","volume":"41","author":"S D\u2019Agosto","year":"2022","unstructured":"D\u2019Agosto S, et al. Loss of FGFR4 promotes the malignant phenotype of PDAC. Oncogene. 2022;41:4371\u201384.","journal-title":"Oncogene"},{"issue":"9","key":"2408_CR44","doi-asserted-by":"publisher","first-page":"e102808","DOI":"10.15252\/embj.2019102808","volume":"39","author":"M Kalisz","year":"2020","unstructured":"Kalisz M, et al. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer. EMBO J. 2020;39(9):e102808.","journal-title":"EMBO J."},{"issue":"10","key":"2408_CR45","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/cancers12102976","volume":"12","author":"N Sasaki","year":"2020","unstructured":"Sasaki N, et al. FGFR4 inhibitor BLU9931 attenuates pancreatic cancer cell proliferation and invasion while inducing senescence: evidence for senolytic therapy potential in pancreatic cancer. Cancers (Basel). 2020;12(10):2976.","journal-title":"Cancers (Basel)."},{"key":"2408_CR46","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/annonc\/mdv591","volume":"27","author":"AW Tolcher","year":"2016","unstructured":"Tolcher AW, et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2016;27:526\u201332.","journal-title":"Ann Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02408-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02408-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:04:07Z","timestamp":1757311447000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02408-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02408-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.02.06.636643","asserted-by":"object"}]},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TMA was obtained under an Institutional Review Board approved protocol at Thomas Jefferson University\n                      23,24\n                      .All animal protocols were approved by The Institute Animal Care and Use Committee (IACUC) at Roswell Park Comprehensive Cancer Center. The animal welfare assurance number for this study is A3143-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}